ArticleHereditas2026
The role of miR-557 in modulating cervical cancer malignancy by targeting TAOK1.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) remains a major threat to women's health globally. Although miR-557 is a tumor suppressor in multiple cancers, its role in CC remains unclear.
objectiveThis study investigated whether miR-557 regulates CC progression by targeting TAOK1.
methodsThis study collected 113 pairs of cervical cancer tissues and adjacent tissues. The expression of miR-557 was detected by qRT-PCR, and its relationship with clinicopathological features and prognosis was analyzed. In HeLa and SiHa cell lines, we performed functional assays (CCK-8, Transwell) and measured ferroptosis-related indicators (Fe²⁺, GSH, GSH-Px) after transfecting miR-557 mimic or TAOK1 overexpression vectors. The miR-557/TAOK1 targeting relationship was validated by dual-luciferase reporter assay and rescue experiments.
resultsmiR-557 was significantly downregulated in CC tissues and cell lines. Low miR-557 expression correlated with advanced FIGO stage, LNM, and poor prognosis. Functionally, miR-557 overexpression inhibited CC cell proliferation, migration, and invasion, accompanied by increased Fe²⁺ levels and decreased GSH and GSH-Px activity. TAOK1 was identified as a direct target of miR-557, and its overexpression reversed the tumor-suppressive effects and ferroptosis-related changes induced by miR-557.
conclusionsmiR-557 is significantly downregulated in CC and exerts tumor-suppressive functions. By targeting TAOK1, it inhibits the malignant progression of CC cells and may act as a promising biomarker for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.